Head to Head Survey: Oric Pharmaceuticals (NASDAQ:ORIC) and Anebulo Pharmaceuticals (NASDAQ:ANEB)

Oric Pharmaceuticals (NASDAQ:ORIC) and Anebulo Pharmaceuticals (NASDAQ:ANEB) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, earnings, analyst recommendations, valuation and dividends.

Risk & Volatility

Oric Pharmaceuticals has a beta of 1.02, meaning that its stock price is 2% more volatile than the S&P 500. Comparatively, Anebulo Pharmaceuticals has a beta of -1.82, meaning that its stock price is 282% less volatile than the S&P 500.

Valuation and Earnings

This table compares Oric Pharmaceuticals and Anebulo Pharmaceuticals”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oric Pharmaceuticals	N/A	N/A	-$129.47 million	($1.35)	-10.09
Anebulo Pharmaceuticals	N/A	N/A	-$8.48 million	($0.19)	-1.58

Oric Pharmaceuticals is trading at a lower price-to-earnings ratio than Anebulo Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

95.1% of Oric Pharmaceuticals shares are held by institutional investors. Comparatively, 28.4% of Anebulo Pharmaceuticals shares are held by institutional investors. 5.7% of Oric Pharmaceuticals shares are held by company insiders. Comparatively, 80.6% of Anebulo Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of current ratings for Oric Pharmaceuticals and Anebulo Pharmaceuticals, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oric Pharmaceuticals	1	2	13	0	2.75
Anebulo Pharmaceuticals	1	0	0	0	1.00

Oric Pharmaceuticals presently has a consensus price target of $19.45, indicating a potential upside of 42.84%. Given Oric Pharmaceuticals’ stronger consensus rating and higher possible upside, equities research analysts clearly believe Oric Pharmaceuticals is more favorable than Anebulo Pharmaceuticals.

Profitability

This table compares Oric Pharmaceuticals and Anebulo Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Oric Pharmaceuticals	N/A	-35.35%	-33.39%
Anebulo Pharmaceuticals	N/A	-74.57%	-68.96%

Summary

Oric Pharmaceuticals beats Anebulo Pharmaceuticals on 7 of the 11 factors compared between the two stocks.

About Oric Pharmaceuticals

ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms, including ORIC-613, an orally bioavailable, highly selective inhibitor of PLK4, in preclinical studies for the treatment of breast cancers. It has a license and collaboration agreement with Voronoi Inc.; a license agreement with Mirati Therapeutics, Inc.; and clinical development collaboration agreement with Pfizer Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.

About Anebulo Pharmaceuticals

Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. The company's lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase II clinical trial to address the unmet medical need for a specific antidote for ACI. Anebulo Pharmaceuticals, Inc. was incorporated in 2020 and is based in Lakeway, Texas.